| abstract |
The present invention refers to a αβ T cell genetically modified to express a recombinant chimeric antigen receptor (CAR), wherein the recombinant CAR comprises (a) an extracellular domain comprising an antigen binding region, (b) a transmembrane domain, (c) a co-stimulatory signaling domain, and (d) an intracellular signaling domain, wherein the extracellular domain comprises the extracellular domain of an NKG2D receptor, and wherein the intracellular signaling domain comprises one immunoreceptor tyrosine-based activation motif (ITAM); the recombinant CAR used to modify the αβ T cell; a pharmaceutical composition comprising the genetically modified αβ T cell; method of treating cancer or tumor using the genetically modified αβΤ cell; and method of preparing the genetically modified αβ T cell. In one embodiment, the genetically modified αβΤ cell comprises a CAR comprising the extracellular domain of NKG2D receptor, an lgG4 hinge region, a CD28 transmembrane domain, a 4-1 BB co-stimulatory signaling domain and a single ITAM-containing DAP 12 domain. |